How to choose the right IBD patients for vedolizumab treatment

Česká verzia

Authors: Tkáčik M.
Authors place of work: Gastroenterologická ambulancia NsP Brezno
Published in the journal: Gastroent Hepatol 2020; 74(1): 44-49
Category: IBD: Review Article
doi: https://doi.org/10.14735/amgh202044

Summary

Currently, there are several types of treatment for inflammatory bowel disease, but it is often difficult to decide on the best treatment. The arrival of new biologics helps us to optimize treatment and improve significantly the course of the disease. Vedolizumab is a monoclonal antibody against integrin α4β7. It is gut selective and inhibits vascular adhesion of leucocytes and their migration to the mucosa of the gut, as well as their interactions with mucosal addresins of the gut wall. It is approved for the treatment of moderate to severe form of ulcerative colitis (UC) and Crohn’s disease. Recent studies confirm higher effectivityhave confirmed it to be more effective and safer than adalimumab (VARSITY clinical trial) in both bionaive and anti-tumor necrosis factor exposed (EVOLVE) patients, with higher clinical and endoscopic remission in patients with UC.

Conflict of Interest: The author declares that the article/ manuscript complies with ethical standards, patient anonymity has been respected, and he states that he has no fi nancial, advisory or other commercial interests in relation to the subject matter.

Publication Ethics: This article/ manuscript has not been published or is currently being submitted for another review. The author agrees to publish his name and e-mail in the published article/ manuscript.

Dedication: The article/ manuscript is not supported by a grant nor has it been created with the support of any company.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for bio medical papers.

Keywords:

vedolizumab – anti-TNF – clinical remission – mucosa healing

Zdroje

1. Bortlík M, Ďuricová D, Douda T et al. Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty: čtvrté, aktualizované vydání. Gastroent Hepatol 2019; 73 (1): 11–24. doi: 10.14735/amgh201911.

2. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 (23): 2462–2476. doi: 10.1056/NEJMoa050 516.

3. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: 2. vydání. Gastroent Hepatol 2012; 66 (1): 12–22.

4. Lukáš M. Současnost a budoucnost v léčbě ulcerózní kolitidy. Gastroent Hepatol 2013; 67 (3): 212–218.

5. Zelinkova Z. Vedolizumab v liečbe ulceróznej kolitídy – štúdia VARSITY v kontexte doterajších dát. Gastroenterol prax 2019; 18 (1): 44–46.

6. Sands BE. The risks and benefits of early immunosuppression and biological therapy. Dig Dis 2012; 30 (Suppl 3): 100–106. doi: 10.1159/000342731.

7. Singh S, George J, Boland BS et al. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis 2018; 12 (6): 635–643. doi: 10.1093/ecco-jcc/jjy004.

8. FierceBiotech. J. Levin. FDA Approves Entyvio to Treat Ulcerative Colitis and Crohn’s Disease. [online]. Available from: https: //www.fiercebiotech.com/biotech/fda-approves-entyvio-to-treat-ulcerative-colitis-and-crohn-s-disease.

9. Takeda. Takeda receives european commission marketing authorisation for Entyvio^® (vedolizumab) for the treatment of ulcerative colitis and Crohn’s disease. [online]. Available from: www.takeda.com/newsroom/newsreleases/2014/takeda-receives-european-commission-marketing-authorisation-for-entyvio-vedolizumab-for-the-treatment-of-ulcerative-colitis-and-crohns-disease/.

10. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369 (8): 699–710. doi: 10.1056/NEJMoa1215734.

11. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369 (8): 711–721. doi: 10.1056/NEJMoa1215739.

12. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147 (3): 618–627. doi: 10.1053/j.gastro.2014.05.008.

13. Colombel JF, Sands BE, Rutgeerts P et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66 (5): 839–851. doi: 10.1136/gutjnl-2015-311079.

14. Raine T. Vedolizumab for inflammatory bowel disease: changing the game, or more of the same. United European Gastroenterol J 2014; 2 (5): 333–344. doi: 10.1177/2050640614550672.

15. Amiot A, Grimaud JC, Peyrin-Biroulet L et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14 (11): 1593–1601. doi: 10.1016/j.cgh.2016.02.016.

16. Shelton E, Allegretti JR, Stevens B et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis 2015; 21 (12): 2879–2885. doi: 10.1097/MIB.0000000000000561.

17. Vivio EE, Kanuri N, Gilbertsen JJ et al. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. J Crohns Colitis 2016; 10 (4): 402–409. doi: 10.1093/ecco-jcc/jjv226.

18. Baumgart DC, Bokemeyer B, Drabik A et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43 (10): 1090–1102. doi: 10.1111/apt.13594.

19. D’Haens GD, Colombel JF, Dubinsky M et al. The efficacy of vedolizumab by disease activity and prior tumour necrosis factor  antagonist failure in patients with ulcerative colitis or Crohn’s disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies. Gastroenterology 2016; 150 (4) (Suppl 1): S804–S805. doi: 10.1016/S0016-5085 (16) 32724-X.

20. Kopylov U, Verstockt B, Biedermann L et al. Effectiveness and safety of vedolizumab in anti-TNF-naïve patients with inflammatory bowel disease – a multicenter retrospective European study. Inflamm Bowel DiS 2018; 24 (11): 2442–2451. doi: 10.1093/ibd/izy155.

21. Sands BE, Peyrin-Biroulet L, Loftus EV Jr et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019; 381 (13): 1215–1226. doi: 10.1056/NEJMoa1905725.

22. European Medicines Agency. Entyvio. 2014. [online]. Available from: http: //www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/002782/human_med_001751.jsp & mid=WC0b01ac058001d124.

23. Danese S, Fiorino G, Fernandes C. Catching the therapeutic window of opportunity in early Crohn’s disease. Curr Drug Targets 2014; 15 (11): 1056–1063. doi: 10.2174/1389450115666140908125738.

24. Bressler B, Mantzaris G, Silverberg M et al. Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study. J Crohn Col 2019; 13 (Suppl 1): S427–S428. doi: 10.1093/ecco-jcc/jjy222.697.

25. Yarur A, Mantzaris G, Silverberg M et al. Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: results from the EVOLVE study. J Crohn Col 2019; 13 (Suppl 1): S400–S401. doi: 10.1093/ecco-jcc/jjy222.697.

26. Gombošová L. Vedolizumab ako prvolíniové biologikum v liečbe ulceróznej kolitídy a Crohnovej choroby – recentné data. Gastroenterol prax 2019; 18 (3): 130–135.

27. Yarur A, Mantzaris JG, Kopylov U et al. Real-world safety of vedolizumab and anti-TNF therapies in biologic-naïve ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study. United European Gastroenterology Journal 2019; 7 (8) (Suppl).